Dry AMD Biomarker Panel for Early Detection and Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods lack effective diagnostic and treatment approaches for dry age-related macular degeneration (AMD), particularly in identifying risk factors and monitoring disease progression, due to the complex interaction of genetic, environmental, and metabolic factors involved in the disease.
Innovation Solution
The methods involve determining the expression or activity levels of specific proteins such as PGC-1α, AKT3, PARP2, SIRT-1, and AMPK in samples, comparing them to normal levels to assess risk and monitor disease progression, and using compounds to modulate these levels to treat dry AMD.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If current diagnostic methods are used for dry AMD, then the disease can be detected, but the precision and reliability of diagnosis is insufficient due to complex genetic, environmental, and metabolic factors
Solution Approach 1:
The patent segments the complex diagnostic process into multiple independent measurement components: detecting expression levels of SIRT-1, AMPK, PGC-1α, PARP2, and AKT3 separately. Each biomarker provides specific diagnostic information about different aspects of RPE dysfunction, allowing comprehensive diagnosis through aggregation of multiple simplified measurements rather than one complex test
Solution Approach 2:
The patent employs a multi-functional diagnostic approach where a single diagnostic system evaluates multiple biomarkers (SIRT-1, AMPK, PGC-1α, PARP2, AKT3) simultaneously. Each biomarker serves multiple purposes: indicating RPE mitochondrial dysfunction, assessing autophagy status, and predicting disease progression risk, thereby providing universal diagnostic value across different disease stages and presentations
2Reliability
If current treatment approaches are used for dry AMD, then treatment can be provided, but effectiveness is limited due to lack of personalized treatment strategies
Solution Approach 1:
The patent applies local quality by tailoring treatment to the specific biomarker profile of each patient. Instead of uniform treatment, the diagnostic results for individual biomarkers (e.g., low SIRT-1 indicating mitochondrial dysfunction, high PARP2 indicating DNA damage) guide selection of targeted therapies, allowing treatment to be optimized for the specific pathological features present in each patient's RPE cells
Solution Approach 2:
The patent utilizes parameter changes by monitoring biomarker expression levels over time to assess treatment response. Changes in SIRT-1, AMPK, PGC-1α, PARP2, or AKT3 levels serve as quantitative parameters that indicate whether treatment is effectively reversing RPE dysfunction, enabling dynamic adjustment of treatment parameters based on measured biological responses
3Loss of time
If early risk identification methods are implemented, then disease progression can be monitored, but the complexity of measuring multiple biomarker levels increases
Solution Approach 1:
The patent implements preliminary action by establishing baseline expression levels of SIRT-1, AMPK, PGC-1α, PARP2, and AKT3 in healthy individuals. These pre-established reference values enable early risk identification by allowing direct comparison of patient biomarker levels against known normal ranges, facilitating early detection before clinical symptoms manifest
Solution Approach 2:
The patent merges multiple biomarker measurements into a unified diagnostic framework. By combining assessment of SIRT-1 (mitochondrial function), AMPK (energy metabolism), PGC-1α (mitochondrial biogenesis), PARP2 (DNA repair), and AKT3 (cell survival), the system creates an integrated early detection tool that leverages the complementary information from each biomarker to improve overall diagnostic accuracy
Data Source
AI summary
The present invention is related to diagnostic, treatment and compound screening methods related to dry age-related macular degeneration (dry AM D). In select embodiments, the methods comprise determining expression or activity levels of NAD-dependent deacetylase sirtuin-1 (SI RT-1), AM P-activated protein kinase (AM PK), poly(adenosine diphosphate ribose) polymerase-2 (PARP2), peroxisome proliferator-activated receptor-gamma coactivator 1-alpha (PGC-Iα) and/or mRNA levels of RAC-gamma serine/threonine-protein kinase (AKT3). In general, higher levels of PARP2, lower levels of PGC-Iα or AKT3 and/or higher acetylation levels of PGC-Iα in the samples are indicative that the subject or cells from which the samples are obtained are susceptible or are suffering from dry AMD.